FO
ZYNE

FT Options’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

FT Options’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$146K Buy
17,500
+15,000
+600% +$159K 0.22% 83
2017
Q2 		$42K Buy
+2,500
New +$49.7K 0.07% 118

Other funds holding ZYNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

FT Options's ZYNE Position: Q3 2017 in Review

FT Options increased its Zynerba Pharmaceuticals, Inc (ZYNE) stake by 600% in Q3 2017, buying an estimated $159K and bringing the position to 17,500 shares worth $146K. The position accounts for 0.22% of the portfolio, ranked #83.

FT Options first reported a position in ZYNE in Q2 2017 and has held it in 2 quarters since. 67 funds tracked by Wall St. Rank hold ZYNE as of Q3 2017.

  • FT Options held 17,500 shares of Zynerba Pharmaceuticals, Inc worth $146K as of Q3 2017.
  • FT Options bought 15,000 Zynerba Pharmaceuticals, Inc shares in Q3 2017, an estimated $159K.
  • Zynerba Pharmaceuticals, Inc made up 0.22% of FT Options's portfolio in Q3 2017, its #83 holding.
  • FT Options first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2017 and has held it in 2 quarters since.
  • 67 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.